Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph J DeGeorge

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Frontiers in Toxicology|August 1, 2025
Stress convulsions in rodents: within a weight-of-evidence framework for human seizure riskJoseph J DeGeorge, Monica R Metea
Biomarkers in Medicine|August 25, 2011
Promise of new translational safety biomarkers in drug development and challenges to regulatory qualificationFrank D Sistare, Joseph J DeGeorge
Methods in Molecular Biology (Clifton, N.J.)|May 2, 2008
Applications of toxicogenomics to nonclinical drug development: regulatory science considerationsFrank D Sistare, Joseph J Degeorge
ILAR Journal|January 6, 2017
Scientific Knowledge and Technology, Animal Experimentation, and Pharmaceutical DevelopmentLewis B Kinter, Joseph J DeGeorge
Toxicologic Pathology|June 7, 2015
Regulatory Forum Commentary* Counterpoint: Dose Selection for Tg.rasH2 Mouse Carcinogenicity StudiesJarig Darbes, Frank D Sistare, Joseph J DeGeorge
Regulatory Toxicology and Pharmacology : RTP|June 24, 2019
Exposure assessments in reproductive and developmental toxicity testing: An IQ-DruSafe industry survey on current practices and experiences in support of exposure-based high dose selectionPaul A Andrews, Mary Ellen McNerney, Joseph J DeGeorge
ILAR Journal|June 28, 2021
A Brief History of Use of Animals in Biomedical Research and Perspective on Non-Animal AlternativesLewis B Kinter, Ron DeHaven, David K Johnson, et al.
Toxicologic Pathology|November 7, 2009
An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical developmentRichard D Storer, Frank D Sistare, M Vijayaraj Reddy, et al.
Chemical Research in Toxicology|January 28, 2009
Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450sMark W Powley, Clay B Frederick, Frank D Sistare, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|April 11, 2016
An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 InhibitorsFrederique M Poulet, Jayanthi J Wolf, Danuta J Herzyk, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Frontiers in Toxicology|August 1, 2025
Stress convulsions in rodents: within a weight-of-evidence framework for human seizure riskJoseph J DeGeorge, Monica R Metea
Biomarkers in Medicine|August 25, 2011
Promise of new translational safety biomarkers in drug development and challenges to regulatory qualificationFrank D Sistare, Joseph J DeGeorge
Methods in Molecular Biology (Clifton, N.J.)|May 2, 2008
Applications of toxicogenomics to nonclinical drug development: regulatory science considerationsFrank D Sistare, Joseph J Degeorge
ILAR Journal|January 6, 2017
Scientific Knowledge and Technology, Animal Experimentation, and Pharmaceutical DevelopmentLewis B Kinter, Joseph J DeGeorge
Toxicologic Pathology|June 7, 2015
Regulatory Forum Commentary* Counterpoint: Dose Selection for Tg.rasH2 Mouse Carcinogenicity StudiesJarig Darbes, Frank D Sistare, Joseph J DeGeorge
Regulatory Toxicology and Pharmacology : RTP|June 24, 2019
Exposure assessments in reproductive and developmental toxicity testing: An IQ-DruSafe industry survey on current practices and experiences in support of exposure-based high dose selectionPaul A Andrews, Mary Ellen McNerney, Joseph J DeGeorge
ILAR Journal|June 28, 2021
A Brief History of Use of Animals in Biomedical Research and Perspective on Non-Animal AlternativesLewis B Kinter, Ron DeHaven, David K Johnson, et al.
Toxicologic Pathology|November 7, 2009
An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical developmentRichard D Storer, Frank D Sistare, M Vijayaraj Reddy, et al.
Chemical Research in Toxicology|January 28, 2009
Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450sMark W Powley, Clay B Frederick, Frank D Sistare, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|April 11, 2016
An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 InhibitorsFrederique M Poulet, Jayanthi J Wolf, Danuta J Herzyk, et al.
Pageof 2